← Back

Wire · operational-macro

J&J files sNDA for Caplyta in bipolar I mania as fifth potential indication

Published

20 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Johnson & Johnson has submitted a supplemental New Drug Application to the US FDA seeking approval for Caplyta to treat adult manic or mixed bipolar I episodes, potentially adding a fifth approved indication for the drug.

This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 11 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You face a new competitor in bipolar mania treatment with J&J pushing Caplyta's approval ahead of Vanda's Bysanti. This could reshape market dynamics and create urgency for differentiation or partnerships in mood disorder therapies.

◆ Coverage

1 source · first reported 11 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalbipolar-disorderclinical-trialsfdapsychiatry